Skip to main content
. 2019 Apr 6;9(7):2084–2099. doi: 10.7150/thno.29463

Figure 1.

Figure 1

HOXB13 is overexpressed in high clinical grade and associated with chemoresistance and patient outcome in lung adenocarcinoma. (A) Expression of HOXB13 in tumor tissues from lung cancer patients by IHC analysis. Upper panel left: Low level of HOXB13 expressed in the pseudo-stratified epithelium. Upper panel middle: Low HOXB13 expression in tracheal gland (black arrow) and transparent cartilage (red arrow). Upper panel right: No HOXB13 expression in normal lung tissue. Lower panel left: Low HOXB13 expression in lung adenocarcinoma. Lower panel middle: High HOXB13 expression in lung adenocarcinoma. Lower panel right: High HOXB13 expression in lymph node metastasized tumor tissue of lung adenocarcinoma. (B) Semi-quantitative analysis of HOXB13 levels in lung adenocarcinoma patients. Unpaired Student's t-test (*p < 0.05, **p < 0.01, ***p < 0.001) analyses were performed to compare the HOXB13 level between different lung adenocarcinoma clinical pathological groups. Increased HOXB13 positively correlated with lung adenocarcinoma patients' progression. (C) Increased HOXB13 expression correlates with poor overall survival in lung adenocarcinoma patients as determined by K-M analysis (p < 0.05, log-rank). (D) HOXB13 is high in cisplatin- and paclitaxel-resistant patients (n=6) compared with that in the sensitive patients (n=9) (Lower panel the second). (E) HOXB13 expression is increased in lung adenocarcinoma in an Oncomine Beer Lung cancer dataset (Unpaired Student's t-test, p < 0.0001) (F) Elevated mRNA expression of HOXB13 correlates with poor overall survival in patients from the Oncomine Beer lung dataset determined by K-M plot analysis (p < 0.05, log-rank). (G) High expression of HOXB13 predicts poor outcome in lung adenocarcinoma patients by K-M plot analysis.